Sheba Meymandi is a Cardiology physician affiliated with Olive View-UCLA Medical Center. OpenAlex indexes 77 publications with 2,374 citations (h-index 25); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
14445 Olive View Dr
Rm 2c 121 Olive View Ucla Medical Center
Sylmar, CA 913421437
Telephone
818-364-4289Registry record last updated 8 Jul 2007.
Clinical trials
- The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease
Sponsor: Olive View-UCLA Education & Research Institute
- Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram
Sponsor: Olive View-UCLA Education & Research Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20211 payment
- Lantheus Medical Imaging, Inc.Program year20211 payment
- BOSTON SCIENTIFIC CORPORATIONProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
100%Angiotensin receptor blocker (ARB)100%Losartan Potassium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Critical analysis of Chagas disease treatment in different countries
Memórias do Instituto Oswaldo Cruz
2022 - Neglected Testing for Neglected Tropical Diseases at the CDC
American Journal of Tropical Medicine and Hygiene
2022 - Recommendations for Screening and Diagnosis of Chagas Disease in the United States
The Journal of Infectious Diseases
2021 - Integration of clinical pharmacists into a heart failure clinic within a safety-net hospital
Journal of the American Pharmacists Association
2021 - Recognition and screening for Chagas disease in the USA
Therapeutic Advances in Infectious Disease
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Sammy Saab, MD
Olive View-UCLA Medical Center
Alisha West, MD
Olive View-UCLA Medical Center
Glenn Mathisen, MD
Olive View-UCLA Medical Center
Bowen Chung, MD
Olive View-UCLA Medical Center
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”